TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32041440

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 0
Study: 36335059

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study: 33921829

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CJLP55 supplement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 28
Study: 33038271

Group type: EXPERIMENTAL
Intervention: 1.2 g/kg alcohol dose
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol dose
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.0 g/kg alcohol dose
Number of subjects: 61
Study: 35448206

Group type: EXPERIMENTAL
Intervention: FORT RCT
Number of subjects: 15
Study: 33975304

Group type: EXPERIMENTAL
Intervention: Social Nutrition Program (additional 27 g of protein/day and social network intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 32672800

Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.5 mg, plus verteporfin photodynamic therapy (vPDT)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg, plus sham PDT
Number of subjects: 322
Study: 36377145

Group type: EXPERIMENTAL
Intervention: Laparoscopic Percutaneous Extra-peritoneal Closure (LPEC)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 296
Study: 32349041

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L reuteri DSM 17938
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L rhamnosus 19070‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L reuteri DSM 12246
Number of subjects: 0

Group type: COMPARATOR
Intervention: L helveticus R0052
Number of subjects: 0

Group type: COMPARATOR
Intervention: L rhamnosus R0011
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacillus clausii strains O/C, SIN, N/R, and T
Number of subjects: 0
Study: 32071176

Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment with treatment rationale
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment without treatment rationale
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 150
Study: 33964104

Group type: EXPERIMENTAL
Intervention: Local probiotics applied to periodontal pocket after scaling and root planning (SRP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) only
Number of subjects: 80
Study: 32000743

Group type: EXPERIMENTAL
Intervention: Sun protection intervention involving presentation, action planning, and SMS messages.
Number of subjects: 487
Study: 34731434

Group type: EXPERIMENTAL
Intervention: Acupoint injection combined with CSEA plus PCEA (AICP group, n=168)
Number of subjects: 307

Group type: COMPARATOR
Intervention: CSEA plus PCEA (CP group, n=139)
Number of subjects: 307
Study: 34080789

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration via intravenous and dorsal pancreatic arterial routes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration
Number of subjects: 30
Study: 36081312

Group type: EXPERIMENTAL
Intervention: 6-week tongue elevation training program consisting of anterior tongue elevation strength and endurance tasks with the Iowa Oral Performance Instrument.
Number of subjects: 27

Group type: COMPARATOR
Intervention: 6-week sham training protocol involving expiratory muscle training at very low intensity.
Number of subjects: 27
Study: 33902778

Group type: EXPERIMENTAL
Intervention: Follow-up study after COVID-19 pandemic
Number of subjects: 207
Study: 36478462

Group type: EXPERIMENTAL
Intervention: Aluminium pancakes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo pancakes
Number of subjects: 15
Study: 34429074

Group type: EXPERIMENTAL
Intervention: Impairment-based care plus PEERC
Number of subjects: 94

Group type: COMPARATOR
Intervention: Impairment-based care
Number of subjects: 94
Study: 35253061

Group type: EXPERIMENTAL
Intervention: Triage bracelets
Number of subjects: 11

Group type: COMPARATOR
Intervention: No triage bracelets (control)
Number of subjects: 11
Study: 33234910

Group type: EXPERIMENTAL
Intervention: Smartphone app reminder for ASA adherence (81 mg twice daily for 35 days)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 195
Study: 36182909

Group type: EXPERIMENTAL
Intervention: Health education intervention provided by trained health professionals using power point presentation and peer group discussion for three days followed by consultations for 6 months.
Number of subjects: 700
Study: 34193677

Group type: EXPERIMENTAL
Intervention: BCAA supplementation for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 18
Study: 32615487

Group type: EXPERIMENTAL
Intervention: Short MHL Program (SMHLP)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 975
Study: 36124619

Group type: EXPERIMENTAL
Intervention: Perturbations with one stride or less of response time
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Perturbations with two strides of response time
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Predictable physical nature of the perturbation
Number of subjects: 13
Study: 33075419

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the hand motor hotspot (hMHS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the anatomical hand knob (HK)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 10
Study: 36331513

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Quad Helix (QH)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both RME and QH
Number of subjects: 72
Study: 34402328

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration <20 hours after chemotherapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Pegfilgrastim administration ≥24 hours after chemotherapy
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Timing of pegfilgrastim administration (earlier or later than 20 hours)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Overall outcomes of pegfilgrastim administration
Number of subjects: 182
Study: 35449997

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA) group
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Overall comparison among groups
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 190
Study: 32108322

Group type: EXPERIMENTAL
Intervention: Intradermal injection of plasma gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dermaroller
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined plasma gel and dermaroller
Number of subjects: 60
Study: 35266048

Group type: EXPERIMENTAL
Intervention: Telestration with augmented reality (AR) during training
Number of subjects: 60
Study: 32467635

Group type: EXPERIMENTAL
Intervention: tropicamide (1%)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: tropicamide (0.5%) + phenylephrine (10%)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group receiving artificial tears
Number of subjects: 95
Study: 35022498

Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI)
Number of subjects: 21
Study: 35346971

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention integrated into DSMES plus one booster session and 24 weeks of home practice supported by a mobile application
Number of subjects: 132

Group type: COMPARATOR
Intervention: Comprehensive DSMES group session (control)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Mindfulness intervention and control
Number of subjects: 132
Study: 32074767

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 3 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix 0.25 mg subcutaneously daily for 3 days)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 99

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Letrozole and GnRH antagonist
Number of subjects: 99
Study: 36001712

Group type: EXPERIMENTAL
Intervention: Olokizumab every 2 weeks
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Olokizumab every 4 weeks
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: COMPARATOR
Intervention: Olokizumab every 2 weeks vs. Adalimumab
Number of subjects: 464

Group type: COMPARATOR
Intervention: Olokizumab every 4 weeks vs. Adalimumab
Number of subjects: 464
Study: 33124472

Group type: EXPERIMENTAL
Intervention: Acute psychosocial stressor
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 164
Study: 33161844

Group type: EXPERIMENTAL
Intervention: NOTCH3 cysteine altering variants
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no nonsynonymous variants in NOTCH3)
Number of subjects: 118
Study: 34555200

Group type: EXPERIMENTAL
Intervention: 11 for Health in Denmark program (IG)
Number of subjects: 1122
Study: 32925992

Group type: COMPARATOR
Intervention: CaOH2 only
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CaOH2+EMD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CaOH2+rhPDGF
Number of subjects: 18
Study: 34371898

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 120
Study: 32553536

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 239

Group type: COMPARATOR
Intervention: Severe disease (control)
Number of subjects: 239
Study: 33077900

Group type: EXPERIMENTAL
Intervention: 3D head-mounted virtual reality (HMD VR)
Number of subjects: 16
Study: 35105809

Group type: EXPERIMENTAL
Intervention: Text reminders encouraging flu vaccination
Number of subjects: 689693

Group type: EXPERIMENTAL
Intervention: Text reminders reminding patients that a flu shot was waiting for them
Number of subjects: 689693

Group type: COMPARATOR
Intervention: Business-as-usual control condition (no messages)
Number of subjects: 689693
Study: 33398561

Group type: EXPERIMENTAL
Intervention: pSOC using the SpyGlass™ DS system
Number of subjects: 28
Study: 32013614

Group type: COMPARATOR
Intervention: Saffron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crocin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35272268

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) of the peroneus longus muscle, 3 times per week for 5 weeks, each session lasting 25 minutes.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 32
Study: 34682601

Group type: EXPERIMENTAL
Intervention: Calls
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Texts
Number of subjects: 1680
Study: 32134436

Group type: EXPERIMENTAL
Intervention: Cataract surgery with clear intraocular lens (IOL)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cataract surgery with yellow intraocular lens (IOL)
Number of subjects: 169
Study: 33095737

Group type: EXPERIMENTAL
Intervention: Online semisupervised active learning framework (OSAM) for multiview PolSAR data classification
Number of subjects: 0
Study: 34017098

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory training
Number of subjects: 17648

Group type: EXPERIMENTAL
Intervention: Spatial, non-verbal reasoning training
Number of subjects: 17648

Group type: EXPERIMENTAL
Intervention: Mental rotation or tangram tasks
Number of subjects: 17648
Study: 34031487

Group type: EXPERIMENTAL
Intervention: 2D model
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 3D model
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 2D model for viral hepatitis, cholestatic cirrhosis, and NASH-associated cirrhosis
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 3D model for alcoholic cirrhosis
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Overall intra-class correlation coefficient (ICC) for 2D measurements
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Overall intra-class correlation coefficient (ICC) for 3D measurements
Number of subjects: 248
Study: 32487264

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 130
Study: 34253678

Group type: EXPERIMENTAL
Intervention: Lifestyle and Empowerment Techniques (LETSGO study) involving patient education, psychosocial support, and promotion of physical activity through a smartphone application for monitoring symptoms and promoting physical activity.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard follow-up programme at control hospitals.
Number of subjects: 0
Study: 33028663

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPC) after IV thrombolysis
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPC)
Number of subjects: 68
Study: 36180610

Group type: EXPERIMENTAL
Intervention: Denosumab (subcutaneous) for osteoporosis, 5 years continuous treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Denosumab (subcutaneous) for osteoporosis
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing of the femur
Number of subjects: 1
Study: 32504701

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 267

Group type: COMPARATOR
Intervention: Bolus midazolam
Number of subjects: 267

Group type: COMPARATOR
Intervention: Titrated midazolam
Number of subjects: 267
Study: 33306314

Group type: EXPERIMENTAL
Intervention: New superficial landmark for axillary venous approach
Number of subjects: 538

Group type: COMPARATOR
Intervention: Conventional landmarks for subclavian venous approach
Number of subjects: 538
Study: 34561195

Group type: EXPERIMENTAL
Intervention: Beta-blockers (yes)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Beta-blockers (no)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Short antiplatelet therapy (1 month)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Prolonged antiplatelet therapy (12 months)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 600
Study: 34678987

Group type: EXPERIMENTAL
Intervention: Low-dose neubotulinum toxin A (Neu-BoNT-A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-dose abobotulinum toxin A (Abo-BoNT-A)
Number of subjects: 52
Study: 32109743

Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) below 3 L
Number of subjects: 83685

Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) above 6 L
Number of subjects: 83685

Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) for bariatric surgery
Number of subjects: 83685

Group type: EXPERIMENTAL
Intervention: Total crystalloid volume (TCV) within ERAS guidelines
Number of subjects: 83685
Study: 33843370

Group type: EXPERIMENTAL
Intervention: Tele-behavioral activation (Tele-BA)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Tele-problem-solving therapy (Tele-PST)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Tele-BA and Tele-PST
Number of subjects: 279
Study: 35419960

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 32811627

Group type: EXPERIMENTAL
Intervention: Virtual counseling and monitoring via telephone calls and/or video chat sessions
Number of subjects: 0
Study: 33616641

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose mycophenolate mofetil
Number of subjects: 0
Study: 36366886

Group type: EXPERIMENTAL
Intervention: Q-122 100 mg, twice daily for 28 days
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo, twice daily for 28 days
Number of subjects: 131
Study: 32598700

Group type: EXPERIMENTAL
Intervention: Eradication therapy (ET) with the addition of the prebiotic Zakofalk (inulin + butyrate)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eradication therapy (ET) with the addition of probiotics (lacto- and bifidobacteria)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eradication therapy (ET) without the addition of pre- or probiotics
Number of subjects: 120
Study: 33923663

Group type: EXPERIMENTAL
Intervention: Synbiotic (Gasteel Plus®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32749938

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab (arm A)
Number of subjects: 241

Group type: COMPARATOR
Intervention: mFOLFOX6 alone (arm B)
Number of subjects: 241
Study: 35039277

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus leuprorelin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 40
Study: 32809153

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions for early-stage PD (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy (potential for use in PD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lessons learned from Alzheimer's research
Number of subjects: 0
Study: 32639373

Group type: EXPERIMENTAL
Intervention: Omegawave (OW) device
Number of subjects: 65

Group type: COMPARATOR
Intervention: Strenuous exercise
Number of subjects: 65

Group type: COMPARATOR
Intervention: Rest day
Number of subjects: 65
Study: 35360106

Group type: EXPERIMENTAL
Intervention: Probiotic dose 2.5 × 10^9 CFU/day (n = 18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Probiotic dose 1 × 10^10 CFU/day (n = 18)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 56
Study: 33850467

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard treatment at outpatient clinic
Number of subjects: 334
Study: 33199470

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 107
Study: 32055717

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF) - 58 Gy/40 fractions, twice daily
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CF) - 51 Gy/20 fractions, once daily
Number of subjects: 331
Study: 35687702

Group type: EXPERIMENTAL
Intervention: Resistance exercise program using an elastic band three days a week for 12 weeks
Number of subjects: 80
Study: 33548487

Group type: EXPERIMENTAL
Intervention: Hand pain
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 13
Study: 33212780

Group type: EXPERIMENTAL
Intervention: Healthy dietary intervention (Mediterranean or low-fat diets)
Number of subjects: 215
Study: 35803550

Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Structured Exercise (SE)
Number of subjects: 50
Study: 33906450

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51

Group type: COMPARATOR
Intervention: All groups (including control and sham)
Number of subjects: 51
Study: 33176569

Group type: EXPERIMENTAL
Intervention: ICD-based case definitions of lupus nephritis (LN)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: ICD-10 code for lupus nephritis (LN)
Number of subjects: 981
Study: 32994159

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 6952

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 6952

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6952

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6952
Study: 32385851

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide 10 or 30 mg every 28 days (minimum/maximum dose: 5/40 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 150
Study: 34023289

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided trigeminal nerve block (UGTNB) with general anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (GEA)
Number of subjects: 40
Study: 33059798

Group type: EXPERIMENTAL
Intervention: Health promotion programs and policies in the workplace
Number of subjects: 26
Study: 36371904

Group type: EXPERIMENTAL
Intervention: Invitation to order HPV‐ss kit (opt‐in)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Directly mailed HPV‐ss kit (send‐to-all)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Reminder letter (control)
Number of subjects: 6000
Study: 33646255

Group type: EXPERIMENTAL
Intervention: Clinical practicum experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-time clinical education experiences
Number of subjects: 0
Study: 32972007

Group type: EXPERIMENTAL
Intervention: SaBang-DolGi walking exercise program for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 35176206

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (both doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simulated efficacy for OwH and HR Chinese patients
Number of subjects: 32
Study: 35809371

Group type: EXPERIMENTAL
Intervention: V590 (5.55 × 10⁷ pfu)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: V590 (all dose levels)
Number of subjects: 232
Study: 34022476

Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CT model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined radiomics-standard CT model
Number of subjects: 0
Study: 32388529

Group type: EXPERIMENTAL
Intervention: Primary care physician consultation
Number of subjects: 5727

Group type: COMPARATOR
Intervention: Dentist consultation
Number of subjects: 5727